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ABSTRACT
Objectives To evaluate the survival of patients with cystic
fibrosis whose lung function has deteriorated to a forced
expiratory volume in one second (FEV1) below 30%
predicted in the recent treatment era and to explore
factors associated with any change in survival.
Design Cohort study.
Setting Adult cystic fibrosis unit in London.
Participants 276 patients (147 (53%) male) whose FEV1
wasfirstobservedtobelessthan30%predictedbetween
1 January 1990 and 31 December 2003.
Main outcome measure Survival during follow-up to 31
December 2007 in two year sub-cohorts.
Results Median survival improved from 1.2 years in the
1990-1 group to 5.3 years in the 2002-3 group, with a
marked improvement in survival from 1994. The use of
nebulised recombinant human DNase was significantly
associated with a reduced risk of death (hazard ratio
0.59,95% confidence interval0.44to 0.79).Significantly
increased risks were associated with a body mass index
under 19 (hazard ratio 1.52, 1.10 to 2.10), long term
oxygen therapy (3.52, 2.49 to 4.99), and nebulised
antibiotics (1.84, 1.05 to 3.22).
Conclusion A marked improvement has occurred in the
survival of patients with cystic fibrosis with an FEV1 less
than 30% predicted. Secondary analyses suggest that
some of this improvement may be due to use of
recombinant human DNase.
INTRODUCTION
Cystic fibrosis is a multi-organ inherited disease char-
acterised by chronic pulmonary infection, resulting in
progressiveairwaysdiseasewithaninexorabledecline
in lung function. Overall, outcomes in cystic fibrosis
are improving, and estimates made in the early 1990s
that median life expectancy would double from 20 to
40yearsofagearebeingrealised.
12Whetherthisisalso
true for patients with late stage disease is less clear. On
the basis of work by Kerem et al in 1992, a forced
expiratory volume in one second (FEV1) of less than
30%predictedhasbeengenerallyacceptedasthelevel
of lung function at which median mortality within two
years is greater than 50%.
3 As a consequence, this
threshold is widely used as an appropriate trigger for
consideration of lung transplantation,
4 although,more
recently, predictive survivorship models have been
developed to facilitate this process.
5
Inthepast20years,severalfactorshavecontributed
to preserving the lung function of patients with cystic
fibrosis,and a thresholdof FEV1 below30% predicted
may no longer have the same clinical relevance. A
more developed understanding of the importance of
nutrition and its relation to lung function has led to a
greater emphasis on intensive nutritional
management.
67 Many new treatments have been
developed during this time, including inhaled
tobramycin,
8 nebulised recombinant human DNase,
9
hypertonic saline,
10 and azithromycin.
11 Recombinant
human DNase has been used widely since the mid-
1990s and has resulted in improved airway clearance,
improved lung function, and fewer exacerbations.
912
Non-invasive ventilation in chronic type 2 respiratory
failure has been practised more extensively, including
as a bridge to transplantation, to palliate troublesome
symptomsofhypercapnoea,andpossiblytoextendlife
inpatientswiththelowestleveloflungfunction.
13Mul-
tidisciplinary clinical teams in specialised cystic fibro-
sis centres have also contributed to improved care.
14
Since the study by Kerem et al, evidence has emerged
to show that median survival may not be as low as two
years,
15 especially if other clinical factors (such as rate
ofdeclineinlungfunction)areconsidered.
16However,
no study has re-evaluated the survival of patients with
cystic fibrosis whose lung function has deteriorated to
an FEV1 below 30% predicted in the recent treatment
era. We set out to do this, hypothesising that most
patients with an FEV1 at this level are now surviving
considerably longer than two years.
3 As a secondary
aim, we explored factors associated with any change
in survival.
METHODS
Since 1965, details of all patients referred to the adult
cystic fibrosis unit at Royal Brompton Hospital and
confirmed to have cystic fibrosis have been systemati-
cally recorded; until 2003, information on 1358
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of cystic fibrosis was based on clinical features and a
positive sweat sodium (>70 mmol/L) or chloride
(>60 mmol/L) result or, in cases with a borderline or
negative sweat test result, the presence of a known dis-
ease causing mutation on each CFTR gene or of an
abnormal nasal potential difference measurement.
Clinical and demographic details were collected at
the first consultation and subsequently updated at
annual review, during clinical stability.
We included in the study all such patients whose
FEV1, during clinical stability, was first observed to
belessthan30%ofthepredictedvaluefortheirheight,
sex,andagebetween1January1990and31December
2003,
17 and we examined their survival through to 31
December 2007. Deaths and the dates of death came
from clinic records; in the 13 cases for which we could
not verify vital status to the end of the study (“lost to
follow-up”), we censored survival at the time of their
last clinic attendance. We excluded patients who sub-
sequently had lung transplantation (n=77), as censor-
ing their survival at the date of their operation would
have introduced variations in survival. This is because
the length of time spent on a transplant list is highly
variable, as factors other than clinical severity are con-
sidered (for example, donor shortages and tissue
matching).
At point of entry into the cohort, we collected infor-
mation on age, sex, percentage of predicted FEV1,
body mass index, sputum microbiology (chronic Pseu-
domonas aeruginosa and Burkholderia cepacia infection;
two positive samples in the preceding six month per-
iod), pancreatic exocrine function status (use of pan-
creatic enzymes), diabetes status (cystic fibrosis
related diabetes: positive oral glucose tolerance test
and glucose monitoring), use of nebulised antibiotics
(any), use of nebulised recombinant human DNase,
use of long term oxygen therapy (>16 hours a day),
and use of non-invasive ventilation. We categorised
patients as being underweight if their body mass
index was below 19.
18 All patients had given informed
written consent for their anonymised clinical details to
be used for research purposes.
Statistical analysis
WeusedStata(version10.1)statisticalsoftwaretoana-
lysedata.Wepresentcategoricaldatawithpercentages
and quantitative data by mean values with standard
deviations.Beforeanalysis,weelectedtocomparesur-
vival in two year sub-cohorts with estimates of median
survival and by Kaplan-Meier survival curves. We
derived unadjusted hazard ratios for death in each
sub-cohort by using Cox’s proportional hazards
regression, having verified the proportionality of
hazards by using an option in Stata that plots survival
curvesforeachcategoryofacovariateversustimeana-
lysis (“log-log” plots). The proportional hazards
assumptionisnotviolatedwhenthecurvesareparallel,
which was the case for our data.
We used a multivariate Cox regression model to
examine clinical and demographic factors that might
be associated with survival; we included in the model
allfactorsthatwethoughtrelevantonclinicalgrounds,
irrespective of their statistical effect on survival. As
very few patients were regularly using non-invasive
ventilation (n=2) or were chronically infected with B
cepacia (n=18), we did not include these factors in the
survival model.
RESULTS
We analysed 276 patients, and table 1 summarises
their characteristics. Overall, 53% (n=147) were male;
at entry to the cohort, the mean age was 25.9 (SD 7.9)
years, the mean FEV1 was 23.9% (4.6%) of the pre-
dictedvalue,and92.3%(n=253)ofpatientsweretaking
pancreatic supplements.
Table 1 also shows measures of survival of patients
in each two year sub-cohort. Median survival
improvedfrom1.2yearsinthe1990-1sub-cohortto5.
Table 1 |Characteristics and measures of survival for each two year sub-cohort
Yearofsub-cohort No No (%) male
Mean (SD)
age (years)
Mean (SD) FEV
1
(% predicted)
Total follow-up
(months)
Median survival
(years)
Crude hazard ratio
(95% CI)
1990-1 33 19 (58) 27.2 (10.1) 23.0 (5.5) 107.8 1.2 1.00
1992-3 66 30 (45) 24.7 (7.5) 22.3 (4.9) 189.6 1.7 1.01 (0.66 to 1.56)
1994-5 44 24 (55) 25.6 (5.6) 24.6 (4.2) 182.9 3.8 0.60 (0.37 to 0.98)
1996-7 54 24 (44) 24.5 (7.6) 25.1 (3.5) 288.1 5.0 0.40 (0.25 to 0.65)
1998-9 27 14 (52) 25.4 (7.7) 25.1 (3.5) 149.3 6.7 0.43 (0.24 to 0.76)
2000-1 22 14 (64) 29.2 (10.0) 23.7 (4.3) 100.1 4.0 0.37 (0.19 to 0.72)
2002-3 30 22 (73) 27.7 (7.6) 24.0 (5.7) 113.7 5.3 0.38 (0.20 to 0.71)
FEV1=forced expiratory volume in one second.
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Fig 1 | Kaplan-Meier survival curves subdivided into seven two
year sub-cohorts from 1990 to 2003, showing survival up to
31 December 2007
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improvement in survival from 1994 to 1997 but little
changethereafter.Thispatternisreflectedintheunad-
justed hazard ratios for each sub-cohort and in the sur-
vival curves shown in figure 1.
Figure 2 summarises, for each sub-cohort, some
measures of disease status and important treatment
modalities at the time of entry to the cohort; also
included are the unadjusted hazard ratios for death in
eachsub-cohort.From1994onwards,a“step”increase
occurred in the use of nebulised recombinant human
DNase; across the entire study period a more gradual
reduction occurred in the proportion of patients who
were, at entry to the cohort, markedly underweight
(body mass index <19). Other parameters, including
the use of nebulised antibiotics and P aeruginosa infec-
tion rates, remained stable over the 13 year period of
study. The beginning of the improvement in survival
coincided with the increase in the proportion of
patients who were using recombinant human DNase
at entry to the cohort.
Table 2 shows the modelled associations between
survival and these parameters. In a multivariate
model, the use of nebulised recombinant human
DNase was significantly associated with a reduced
risk of death (hazard ratio 0.59, 95% confidence inter-
val 0.44 to 0.79). Significantly increased risks were
associated with a body mass index below 19 (hazard
ratio 1.52, 1.10 to 2.10) and the use of both long term
oxygentherapy(3.52,2.49to4.99)andnebulisedanti-
biotics (1.84, 1.05 to 3.22). After the inclusion of a bin-
ary term for entry into the cohort pre-1996/post-1995
(hazardratio0.62,0.43to0.89),theuseofrecombinant
human DNase was no longer significantly associated
with improved survival (0.78, 0.55 to 1.11) but the
other associations were essentially unchanged.
DISCUSSION
Our findings show an important improvement in the
average survival of patients with cystic fibrosis whose
lung function (forced expiratory volume in one sec-
ond) has fallen below 30% of their predicted value.
Median survival for patients who entered the cohort
most recently (2002-3) was 5.3 years, more than twice
thatforthosewhoenteredthestudyintheearly1990s,
when median survival was less than two years, similar
to the value published by Kerem et al in 1992.
3 Inter-
estingly,survivaldidnotincreasesteadilyovertheper-
iod of our study; rather, an obvious stepwise
improvement occurred from 1994 to 1997 with little
further change thereafter. Over the same period, we
recorded important changes in disease status and
some treatment modalities. Nebulised recombinant
human DNase first received a UK licence in 1994,
which explains the striking increase in its use from
this year; 80% of the subsequently enrolled cohort
receivedit.Asteadyimprovementinnutritionalstatus
also occurred, from 73% of patients underweight in
1990 to around 50% in the early 2000s. Other para-
meters included in our study were relatively
unchanged over this time.
Comparison with other studies
SincethestudybyKeremetal,
3twootherNorthAmer-
icanstudiesfromthelate1990shavesuggestedthatthe
median survival of patients with a forced expiratory
volume in one second below 30% predicted is better
than two years, showing survival of at least 3.9 years
in their centres.
1516 Our study included a much larger
study population, examining survival from 1990 for a
further 17 years, thus incorporating a more contem-
porary era of management and treatment. A median
survival of 5.3 years confirms a further step improve-
mentandhighlightsthedifficultchallengeofdetermin-
ingwhenpatientsaregenuinely“endstage”andshould
thus be referred for transplantation. This was also
shown by a study that used predictive survivorship
models and concluded that five year survival varied
between 6% and 94% when forced expiratory volume
inonesecondwasbelow30%predictedandthatsurvi-
val was superior for non-transplanted patients for the
first 2.5 years of follow-up.
5
An independent association of nebulised recombi-
nant human DNase with improved survival was evi-
dent on regression analysis, which suggested that its
use was related to a 41% reduction in mortality. Of
the other treatments we examined, both were asso-
ciated with an increase in mortality, presumably
Table 2 |Multivariate Cox regression analysis of some measures of disease status and important treatment modalities at time of entry to cohort. Values are
numbers (percentages) unless stated otherwise
Variable Alive (n=65) Dead (n=211)
Univariate model Multivariate model*
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Mean (SD) age (years) 26.7 (7.5) 25.6 (8.1) 0.98 (0.97 to 1.00) 0.07 0.99 (0.97 to 1.01) 0.54
Male sex 46 (71) 101 (48) 0.74 (0.57 to 0.98) 0.03 0.89 (0.66 to 1.18) 0.41
Body mass index <19 35/63 (56) 144/208 (69) 1.70 (1.26 to 2.29) <0.001 1.52 (1.10 to 2.10) 0.011
Pancreatic insufficiency 56/65 (86) 197/209 (94) 1.63 (0.91 to 2.92) 0.10 0.91 (0.46 to 1.80) 0.79
Chronic Pseudomonas aeruginosa infection 39/61 (64) 189/209 (90) 2.16 (1.39 to 3.37) 0.001 1.18 (0.79 to 1.76) 0.41
Cystic fibrosis related diabetes 10/64 (16) 62 (29) 1.58 (1.78 to 2.13) 0.003 1.28 (0.92 to 1.79) 0.14
Use of recombinant human DNase 50 (77) 111 (53) 0.57 (0.44 to 0.75) <0.001 0.59 (0.44 to 0.79) <0.001
Use of nebulised antibiotics 43/60 (72) 177/211 (84) 2.22(1.40 to 3.54) 0.001 1.84 (1.05 to 3.22) 0.033
Use of long term oxygen therapy 2/62 (3) 60/207 (29) 4.47 (3.27 to 6.16) <0.001 3.52 (2.49 to 4.99) <0.001
*Includes all variables listed in table.
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patients. Our study is observational, and, as very few
patients were prescribed recombinant human DNase
before 1994 and almost all were after this date, disen-
tangling its effects from other (unmeasured) factors
with a temporal trend across the period of our study
is statistically difficult. However, the ecological rela-
tion between the use of recombinant human DNase
and the improvement in survival and the magnitude
of its effect in the regression analysis are compelling
observations. Nebulised recombinant human DNase
has been shown in controlled trials to improve lung
function, reduce pulmonary exacerbations, and mod-
ulate airway inflammation in cystic fibrosis, but it has
not previously been shown to improve survival.
919A
recent Cochrane systematic review also confirmed
these findings.
20 The rapidity with which survival
improved after the widespread use of this treatment
in our cohort is, in our view, biologically plausible, as
studies of the drug have shown benefits on lung func-
tionfromasearlyasoneweekandcontinuinguptotwo
years.
91221
Underweight patients were at significantly greater
risk of death; those whose body mass index was less
than 19 at entry, a commonly used trigger for escalat-
ing nutritional intervention in cystic fibrosis,
18 had an
independentincreaseinmortalityof52%.Thisfinding
supports a well established concept but importantly
also shows its clinical significance when lung function
is poor. Since the introduction of enteric coated pan-
creatic enzymes in the 1980s, huge progress has been
made in the nutritional status of patients with cystic
fibrosis.
22 Other factors, including chronic infection
with P aeruginosa, cystic fibrosis related diabetes, and
sex, were significant only on univariate analysis. The
first two are widely accepted to be associated with a
worse outcome in cystic fibrosis.
623-25 Female sex has
alsobeenshowntohaveadeleteriouseffect,
26although
somepeoplearguethatthisisareflectionofconfound-
ing by other factors, such as a worse nutritional state.
6
Strengths and limitations of study
We recognise several limitations to our study. Our
patients were recruited from a single centre, and a
small number were lost to follow up. Although we
doubt that this detracts from the generalisability or
accuracy of our findings, other cystic fibrosis centres
need to examine survival in this population of espe-
cially sick patients. We examined determinants of sur-
vival only at entry to the cohort rather than during the
period of follow-up. We did this because we wanted to
consider the prognostic value of these factors at the
point at which lung function fell below 30% predicted;
infact,atimedependentanalysiswouldprobablyhave
made little difference to our findings, as most if not all
ofthevariablesweexaminedwouldbeunvaryingover
time. We could not examine the benefits of treatments
for cystic fibrosis such as azithromycin and hypertonic
saline,asmostofthecohortpre-datestheirwidespread
use after the publication of large randomised con-
trolled trials.
1011 Hypertonic saline is an effective neb-
ulised mucolytic, but unlike recombinant human
DNase it cannot be said to lead to an improvement in
lung function in the long term.
27 Finally, for reasons
givenearlier,weexcludedfromanalysisthosepatients
in the cohort who had had lung transplantation. We
consideredwhetherchangesintheselectionofpatients
for transplant over the period of the study might have
resulted in a non-transplant group with more favour-
ablesurvival.Wethinkthatthisisunlikely,asweknow
of no such systematic change in approach during the
period of our study; moreover, the proportion of
cohort patients who had transplantation fell steadily
from 28% (n=13) in the 1990-1 sub-cohort to 14%
(n=5) in the final (2002-3) sub-cohort.
This study highlights the importance of, and neces-
sityfor,usingwellconductedobservationalmethodsin
chronicmedicalconditionsforwhichlargeprospective
controlled trials with outcome measures such as mor-
tality are almost impossible to do effectively. No inter-
ventional study in cystic fibrosis has yet shown a
benefit on mortality, and even large trials in chronic
obstructive pulmonary disease have been hampered
by insufficient statistical power and have failed to
reach their primary end point.
28 We believe the sys-
tematic collection of patients’ data through registries
with carefully constructed analysis will continue to
play a vital role in informing clinicians’ practice and
optimising patients’ outcomes.
Conclusions and policy implications
The implications of our study are several. Short of
developingacureforcysticfibrosis,improvedsurvival
is a principal goal, and treatment strategies aim to do
this.Thethreshold of30% predictedforforced expira-
toryvolumeinonesecondshouldnolongerbeconsid-
ered in isolation as the start of end stage lung disease
and consideration for lung transplantation. The
reasonsfortheimprovementinsurvivalarealmostcer-
tainly multifactorial, but providing a multidisciplinary
approach, with attention to details such as nutrition
and airway clearance, is likely to be a key element in
maintaining health even at low levels of lung function.
In conclusion, we have shown that the survival of
patients with cystic fibrosis whose lung function
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edly, with a median predicted survival now of 5.
3 years. This finding will help to inform patients and
relatives, assist clinicians in managing their individual
patients appropriately, and inform policy makers on
timing of interventions with implications on resource
allocation.
The study was supported by the Respiratory Biomedical Research Unit
(BRU) at the Royal Brompton Hospital; MEH, DB, and NJS are part of the
Chronic Suppurative Lung Disease (CSLD) research consortium of the
Respiratory BRU. We acknowledge the input of Khin Gyi for supporting
the data collection process that proved invaluable to the study.
Contributors: PMG contributed to conception and design, acquisition of
data, analysis and interpretation of data, drafting the article, and final
approval of the version to be published. WB contributed to design,
statistical analysis and interpretation of data, and final approval of the
version to be published. NP contributed to design, acquisition and
analysis of data, and final approval of the version to be published. DB
contributed to the conception, design, analysis and interpretation of the
d a t a ,a n df i n a la p p r o v a lo ft h ev e r s i o nt ob ep u b l i s h e d .P Cc o n t r i b u t e dt o
design, statistical analysis and interpretation of data, drafting the article,
and final approval of the version to be published. MEH contributed to
conception and design, analysis and interpretation of data, and final
approval of the version to be published. NJS contributed to conception
and design, acquisition of data, analysis and interpretation of data,
drafting the article, and coordinating the study. NJS is the guarantor.
Funding: No external funding.
Competing interests: All authors have completed the Unified Competing
Interest form at www.icmje.org/coi_disclosure.pdf (available on request
from the corresponding author) and declare that they have no
relationships with any company that might have an interest in the
submittedworkintheprevious3years;nordotheirspouses,partners,or
children have any financial relationships that may be relevant to the
submitted work; and they have no non-financial interests that may be
relevant to the submitted work.
Ethical approval: The Royal Brompton Hospital Ethics Committee has
approved use of the data for this purpose.
Data sharing: No additional data available.
1 Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current survival and
population estimates to the year 2000. Thorax 1991;46:881-5.
2 Hodson ME, Simmonds NJ, Warwick WJ, Tullis E, Castellani C,
Assael B, et al. An international/multicentre report on patients with
cystic fibrosis (CF) over the age of 40 years. JC y s tF i b r o s
2008;7:537-42.
3 K e r e mE ,R e i s m a nJ ,C o r e yM ,C a n n yG J ,L e v i s o nH .P r e d i c t i o no f
mortality in patients with cystic fibrosis. NE n g lJM e d
1992;326:1187-91.
4 O r e n sJ B ,E s t e n n eM ,A r c a s o yS ,C o n t eJ V ,C o r r i sP ,E g a nJ J ,e ta l .
International guidelines for the selection of lung transplant
candidates: 2006 update—a consensus report from the Pulmonary
Scientific Council of the International Society for Heart and Lung
Transplantation. J Heart Lung Transplant 2006;25:745-55.
5 LiouTG,AdlerFR,CahillBC,FitzsimmonsSC,HuangD,HibbsJR,etal.
Survival effect of lung transplantation among patients with cystic
fibrosis. JAMA 2001;286:2683-9.
6 Corey M, Farewell V. Determinants of mortality from cystic fibrosis in
Canada, 1970-1989. Am J Epidemiol 1996;143:1007-17.
7 SteinkampG,WiedemannB.Relationshipbetweennutritionalstatus
and lung function in cystic fibrosis: cross sectional and longitudinal
analyses from the German CF quality assurance (CFQA) project.
Thorax 2002;57:596-601.
8 Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR,
Kravitz RM, et al. Efficacy of aerosolized tobramycin in patients with
cystic fibrosis. NE n g lJM e d1993;328:1740-6.
9 Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML,
Ramsey BW, et al. Effect of aerosolized recombinant human DNase
on exacerbations of respiratory symptoms and on pulmonary
function in patients with cystic fibrosis. NE n g lJM e d
1994;331:637-42.
10 Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB,
et al. A controlled trial of long-term inhaled hypertonic saline in
patients with cystic fibrosis. NE n g lJM e d2006;354:229-40.
11 Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL,
Cibene DA, et al. Azithromycin in patients with cystic fibrosis
chronically infected with Pseudomonas aeruginosa: a randomized
controlled trial. JAMA 2003;290:1749-56.
1 2 S h a hP L ,S c o t tS F ,F u c h sH J ,G e d d e sD M ,H o d s o nM E .M e d i u mt e r m
treatment of stable stage cystic fibrosis with recombinant human
DNase I. Thorax 1995;50:333-8.
13 Madden BP, Kariyawasam H, Siddiqi AJ, Machin A, Pryor JA,
Hodson ME. Noninvasive ventilation in cystic fibrosis patients with
acute or chronic respiratory failure. Eur Respir J 2002;19:310-3.
14 MahadevaR,Webb K,WesterbeekRC,CarrollNR,DoddME,BiltonD,
et al. Clinical outcome in relation to care in centres specialising in
cystic fibrosis: cross sectional study. BMJ 1998;316:1771-5.
15 Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with
severely compromised lung function. Chest 1998;113:1230-4.
16 Doershuk CF, Stern RC. Timing of referral for lung transplantation for
cystic fibrosis: overemphasis on FEV1 may adversely affect overall
survival. Chest 1999;115:782-7.
17 Gibson GJ. Standardised lung function testing. Eur Respir J
1993;6:155-7.
18 UK Cystic Fibrosis Trust Nutrition Working Group. Nutritional
management of cystic fibrosis. Cystic Fibrosis Trust, 2002.
19 PaulK,RietschelE,BallmannM,GrieseM,WorlitzschD,ShuteJ,etal.
Effect of treatment with dornase alpha on airway inflammation in
patients with cystic fibrosis. Am J Respir Crit Care Med
2004;169:719-25.
20 Jones AP, Wallis C. Dornase alfa for cystic fibrosis. Cochrane
Database Syst Rev 2010;3:CD001127.
2 1 Q u a nJ M ,T i d d e n sH A ,S yJ P ,M c K e n z i eS G ,M o n t g o m e r yM D ,
RobinsonPJ,etal.Atwo-yearrandomized,placebo-controlledtrialof
dornase alfa in young patients with cystic fibrosis with mild lung
function abnormalities. JP e d i a t r2001;139:813-20.
22 Mischler EH, Parrell S, Farrell PM, Odell GB. Comparison of
effectiveness of pancreatic enzyme preparations in cystic fibrosis.
Am J Dis Child 1982;136:1060-3.
23 Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL.
Pseudomonas aeruginosa and other predictors of mortality and
morbidity in young children with cystic fibrosis. Pediatr Pulmonol
2002;34:91-100.
24 Finkelstein SM, Wielinski CL, Elliott GR, Warwick WJ, Barbosa J,
Wu SC, et al. Diabetes mellitus associated with cystic fibrosis. J
Pediatr 1988;112:373-7.
25 MillaCE,BillingsJ,MoranA.Diabetesisassociatedwithdramatically
decreased survival in female but not male subjects with cystic
fibrosis. Diabetes Care 2005;28:2141-4.
26 Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender
gap in cystic fibrosis mortality. Am J Epidemiol 1997;145:794-803.
27 Wark P, McDonald VM. Nebulised hypertonic saline for cystic
fibrosis. Cochrane Database Syst Rev 2009;2:CD001506.
28 Calverley PM,Anderson JA, Celli B, FergusonGT,JenkinsC, JonesPW,
et al. Salmeterol and fluticasone propionate and survival in chronic
obstructive pulmonary disease. NE n g lJM e d2007;356:775-89.
Accepted: 31 December 2010
WHAT IS ALREADY KNOWN ON THIS TOPIC
A forced expiratory volume in one second (FEV1) below 30% of the predicted value is
generally considered the threshold at which 50% of patients with cystic fibrosis survive two
years or less
Modern cystic fibrosis management over the past two decades may have led to improved
outcomes, but this has not been shown in patients with severely impaired lung function
Certain clinical factors, such as a higher body mass index, are associated with better
outcomes
WHAT THIS STUDY ADDS
Median survivalofpatients withcystic fibrosisand FEV1 below 30% increased from1.2years
in the 1990-1 sub-cohort to 5.3 years in the 2002-3 sub-cohort
A clear stepwise improvement from 1994 to 1997 (with little further change thereafter)
coincided with the introduction of nebulised recombinant human DNase
A steady improvement in body mass index also occurred; body mass index below 19 was
associated with an increased risk of death
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